EirGen Pharma Product Eir-102 Passes Bioequivalence Study in US

EirGen Pharma are pleased to announce that our product Eir-102 has successfully passed its Bioequivalence Study against the US Reference Product. This is a first to file generic product indicated for the treatment of prostate cancer and we expect to complete our filing to US FDA shortly.